PRXL2A

Across TCGA pan-cancer cohorts, PRXL2A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRXL2A data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRXL2A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRXL2A expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PRXL2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	II,III,IV	0.973	0.771	.007	26	view →
LUAD	DFS	Median	II,III,IV	0.773	1.000	.005	13	view →
CCRCC	DFS	Median	III,IV	0.928	0.128	.014	12	view →
LSCC	DFS	Quartile	All	0.987	0.848	.004	10	view →
PDAC	DFS	Median	All	0.884	0.718	.003	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRXL2A–HNSC (OS)

Open the HNSC breakdown →